Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)

Peter H. Wiernik; Zhuoxin Sun; Holly Gundacker; Gordon Dewald; Marilyn L. Slovak; Elisabeth Paietta; Haesook T. Kim; Frederick R. Appelbaum; Peter A. Cassileth; Martin S. Tallman

doi:10.1007/s12032-012-0251-7

Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)

Peter H. Wiernik, Zhuoxin Sun, Holly Gundacker, Gordon Dewald, Marilyn L. Slovak, Elisabeth Paietta, Haesook T. Kim, Frederick R. Appelbaum, Peter A. Cassileth, Martin S. Tallman

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

This retrospective study performed by the Eastern Cooperative Oncology Group and the Southwest Oncology Group enrolled 140 acute promyelocytic leukemia (APL) patients with t(15;17) to determine the influence of additional karyotypic abnormalities on treatment outcome. Karyotypes were centrally reviewed by both study groups. The complete response rate after induction for patients with t(15;17) treated with chemotherapy, or alltrans retinoic acid (ATRA) as induction therapy was not affected by additional cytogenetic aberrations. Disease-free (DFS) and overall survival (OS) were unaffected by additional cytogenetic abnormalities if treatment was chemotherapy without ATRA. Patients with t(15;17) only, treated with ATRA with or without chemotherapy, had an improved DFS (P = 0.06) and a better OS (P = 0.01) compared with ATRA-treated patients with additional cytogenetic abnormalities. Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities.

Original language	English (US)
Pages (from-to)	2095-2101
Number of pages	7
Journal	Medical Oncology
Volume	29
Issue number	3
DOIs	https://doi.org/10.1007/s12032-012-0251-7
State	Published - Sep 2012
Externally published	Yes

Keywords

Acute promyelocytic leukemia
All-trans retinoic acid
Karyotype
T(15;17)

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12032-012-0251-7

Cite this

@article{29d7e924ac834c619b558a801ed73e6b,

title = "Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)",

abstract = "This retrospective study performed by the Eastern Cooperative Oncology Group and the Southwest Oncology Group enrolled 140 acute promyelocytic leukemia (APL) patients with t(15;17) to determine the influence of additional karyotypic abnormalities on treatment outcome. Karyotypes were centrally reviewed by both study groups. The complete response rate after induction for patients with t(15;17) treated with chemotherapy, or alltrans retinoic acid (ATRA) as induction therapy was not affected by additional cytogenetic aberrations. Disease-free (DFS) and overall survival (OS) were unaffected by additional cytogenetic abnormalities if treatment was chemotherapy without ATRA. Patients with t(15;17) only, treated with ATRA with or without chemotherapy, had an improved DFS (P = 0.06) and a better OS (P = 0.01) compared with ATRA-treated patients with additional cytogenetic abnormalities. Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities.",

keywords = "Acute promyelocytic leukemia, All-trans retinoic acid, Karyotype, T(15;17)",

author = "Wiernik, {Peter H.} and Zhuoxin Sun and Holly Gundacker and Gordon Dewald and Slovak, {Marilyn L.} and Elisabeth Paietta and Kim, {Haesook T.} and Appelbaum, {Frederick R.} and Cassileth, {Peter A.} and Tallman, {Martin S.}",

note = "Funding Information: Acknowledgments Supported in part by DHHS grants from the National Cancer Institute, National Institutes of Health grants CA21115, ECOG; CA91151 (PHW), and CA32102, SWOG Leukemia, and Cytogenetics Program. Presented in part at the national meeting of the American Society of Hematology, 2001.",

year = "2012",

month = sep,

doi = "10.1007/s12032-012-0251-7",

language = "English (US)",

volume = "29",

pages = "2095--2101",

journal = "Medical Oncology",

issn = "1357-0560",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

TY - JOUR

T1 - Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)

AU - Wiernik, Peter H.

AU - Sun, Zhuoxin

AU - Gundacker, Holly

AU - Dewald, Gordon

AU - Slovak, Marilyn L.

AU - Paietta, Elisabeth

AU - Kim, Haesook T.

AU - Appelbaum, Frederick R.

AU - Cassileth, Peter A.

AU - Tallman, Martin S.

N1 - Funding Information: Acknowledgments Supported in part by DHHS grants from the National Cancer Institute, National Institutes of Health grants CA21115, ECOG; CA91151 (PHW), and CA32102, SWOG Leukemia, and Cytogenetics Program. Presented in part at the national meeting of the American Society of Hematology, 2001.

PY - 2012/9

Y1 - 2012/9

N2 - This retrospective study performed by the Eastern Cooperative Oncology Group and the Southwest Oncology Group enrolled 140 acute promyelocytic leukemia (APL) patients with t(15;17) to determine the influence of additional karyotypic abnormalities on treatment outcome. Karyotypes were centrally reviewed by both study groups. The complete response rate after induction for patients with t(15;17) treated with chemotherapy, or alltrans retinoic acid (ATRA) as induction therapy was not affected by additional cytogenetic aberrations. Disease-free (DFS) and overall survival (OS) were unaffected by additional cytogenetic abnormalities if treatment was chemotherapy without ATRA. Patients with t(15;17) only, treated with ATRA with or without chemotherapy, had an improved DFS (P = 0.06) and a better OS (P = 0.01) compared with ATRA-treated patients with additional cytogenetic abnormalities. Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities.

AB - This retrospective study performed by the Eastern Cooperative Oncology Group and the Southwest Oncology Group enrolled 140 acute promyelocytic leukemia (APL) patients with t(15;17) to determine the influence of additional karyotypic abnormalities on treatment outcome. Karyotypes were centrally reviewed by both study groups. The complete response rate after induction for patients with t(15;17) treated with chemotherapy, or alltrans retinoic acid (ATRA) as induction therapy was not affected by additional cytogenetic aberrations. Disease-free (DFS) and overall survival (OS) were unaffected by additional cytogenetic abnormalities if treatment was chemotherapy without ATRA. Patients with t(15;17) only, treated with ATRA with or without chemotherapy, had an improved DFS (P = 0.06) and a better OS (P = 0.01) compared with ATRA-treated patients with additional cytogenetic abnormalities. Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities.

KW - Acute promyelocytic leukemia

KW - All-trans retinoic acid

KW - Karyotype

KW - T(15;17)

UR - http://www.scopus.com/inward/record.url?scp=84872820174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872820174&partnerID=8YFLogxK

U2 - 10.1007/s12032-012-0251-7

DO - 10.1007/s12032-012-0251-7

M3 - Article

C2 - 22729365

AN - SCOPUS:84872820174

SN - 1357-0560

VL - 29

SP - 2095

EP - 2101

JO - Medical Oncology

JF - Medical Oncology

IS - 3

ER -

Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this